luigi fattore
luigi fattore
PostDoc presso Istituto Nazionale Tumori Regina Elena
Nessuna email verificata
Citata da
Citata da
Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial
P Ponikowski, BA Kirwan, SD Anker, T McDonagh, M Dorobantu, ...
The Lancet 396 (10266), 1895-1904, 2020
miR-579-3p controls melanoma progression and resistance to target therapy
L Fattore, R Mancini, M Acunzo, G Romano, A Laganà, ME Pisanu, ...
Proceedings of the National Academy of Sciences 113 (34), E5005-E5013, 2016
MicroRNAs in melanoma development and resistance to target therapy
L Fattore, S Costantini, D Malpicci, CF Ruggiero, PA Ascierto, CM Croce, ...
Oncotarget 8 (13), 22262, 2017
Activation of an early feedback survival loop involving phospho-ErbB3 is a general response of melanoma cells to RAF/MEK inhibition and is abrogated by anti-ErbB3 antibodies
L Fattore, E Marra, ME Pisanu, A Noto, C de Vitis, F Belleudi, L Aurisicchio, ...
Journal of translational medicine 11 (1), 1-11, 2013
Early risks of death, stroke/systemic embolism, and major bleeding in patients with newly diagnosed atrial fibrillation: results from the GARFIELD-AF registry
JP Bassand, S Virdone, SZ Goldhaber, AJ Camm, DA Fitzmaurice, ...
Circulation 139 (6), 787-798, 2019
Combination therapy with anti-ErbB3 monoclonal antibodies and EGFR TKIs potently inhibits non-small cell lung cancer
A Noto, C De Vitis, G Roscilli, L Fattore, D Malpicci, E Marra, L Luberto, ...
Oncotarget 4 (8), 1253, 2013
Monoclonal antibody-induced ErbB3 receptor internalization and degradation inhibits growth and migration of human melanoma cells
F Belleudi, E Marra, F Mazzetta, L Fattore, MR Giovagnoli, R Mancini, ...
Cell Cycle 11 (7), 1455-1467, 2012
Reprogramming miRNAs global expression orchestrates development of drug resistance in BRAF mutated melanoma
L Fattore, CF Ruggiero, ME Pisanu, D Liguoro, A Cerri, S Costantini, ...
Cell Death & Differentiation 26 (7), 1267-1282, 2019
Inhibition of Stearoyl-CoA desaturase 1 reverts BRAF and MEK inhibition-induced selection of cancer stem cells in BRAF-mutated melanoma
ME Pisanu, M Maugeri-Saccà, L Fattore, S Bruschini, C De Vitis, E Tabbì, ...
Journal of Experimental & Clinical Cancer Research 37 (1), 1-17, 2018
Single cell analysis to dissect molecular heterogeneity and disease evolution in metastatic melanoma
L Fattore, CF Ruggiero, D Liguoro, R Mancini, G Ciliberto
Cell death & disease 10 (11), 1-12, 2019
Management and 1‐year outcomes of patients with newly diagnosed atrial fibrillation and chronic kidney disease: results from the prospective GARFIELD‐AF registry
S Goto, P Angchaisuksiri, JP Bassand, AJ Camm, H Dominguez, ...
Journal of the American Heart Association 8 (3), e010510, 2019
Selective targeting of point-mutated KRAS through artificial microRNAs
M Acunzo, G Romano, G Nigita, D Veneziano, L Fattore, A Laganà, ...
Proceedings of the National Academy of Sciences 114 (21), E4203-E4212, 2017
Toxicity of aflatoxin B1 towards the vitamin D receptor (VDR)
P Costanzo, A Santini, L Fattore, E Novellino, A Ritieni
Food and Chemical Toxicology 76, 77-79, 2015
TrkB is responsible for EMT transition in malignant pleural effusions derived cultures from adenocarcinoma of the lung
A Ricci*, C De Vitis*, A Noto*, L Fattore, S Mariotta, E Cherubini, G Roscilli, ...
Cell cycle 12 (11), 1696-1703, 2013
Combination of antibodies directed against different ErbB3 surface epitopes prevents the establishment of resistance to BRAF/MEK inhibitors in melanoma
L Fattore, D Malpicci, E Marra, F Belleudi, A Noto, C De Vitis, ME Pisanu, ...
Oncotarget 6 (28), 24823, 2015
Role of WT1–ZNF224 interaction in the expression of apoptosis-regulating genes
G Montano, E Cesaro, L Fattore, K Vidovic, C Palladino, R Crescitelli, ...
Human Molecular Genetics 22 (9), 1771-1782, 2013
MicroRNA-driven deregulation of cytokine expression helps development of drug resistance in metastatic melanoma
L Fattore, A Sacconi, R Mancini, G Ciliberto
Cytokine & Growth Factor Reviews 36, 39-48, 2017
CytoMatrix for a reliable and simple characterization of lung cancer stem cells from malignant pleural effusions
S Bruschini, S di Martino, ME Pisanu, L Fattore, C De Vitis, V Laquintana, ...
Journal of cellular physiology 235 (3), 1877-1887, 2020
microRNA-378a-5p iS a novel positive regulator of melanoma progression
MG Tupone, S D’Aguanno, M Di Martile, E Valentini, M Desideri, ...
Oncogenesis 9 (2), 1-13, 2020
ErbB3 phosphorylation as central event in adaptive resistance to targeted therapy in metastatic melanoma: Early detection in CTCs during therapy and insights into regulation by …
CF Ruggiero, D Malpicci, L Fattore, G Madonna, V Vanella, D Mallardo, ...
Cancers 11 (10), 1425, 2019
Il sistema al momento non può eseguire l'operazione. Riprova più tardi.
Articoli 1–20